Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5465-5475

  Chang, Kwok Chiu ^a   Leung, Chi Chiu ^a   Yew, Wing Wai ^b   Leung, Eric Chung Ching ^a   Leung, Wai Man ^a   Tam, Cheuk Ming ^a   Zhang, Ying ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG USE; EPIDEMIOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT OUTCOME;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; RISK; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84868014521     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01300-12     Document Type: Article

References (45)

1. Chan ED, Strand MJ, Iseman MD. 2009. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin. Infect. Dis. 48:e50-e52.
2. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. 2008. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am. J. Respir. Crit. Care Med. 177:1391-1396.
3. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505.
4. Dalmer O, Walter E, Firma E. 1936. Merck in Darmstadt. Verfahren zur Herstellung von Abkömmlingen der Pyrazinmonocarbonsäure. Patentiert im Deutschen Reiche vom 8. Juli 1934 ab. German patent 632 257 Klasse 12 p Gruppe 6 M 127990 IV a/12 p.
5. East African/British Medical Research Council. 1974. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet ii:1100-1106.
6. East African/British Medical Research Council. 1976. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study. Am. Rev. Respir. Dis. 114:471-475.
7. East African/British Medical Research Council. 1978. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/ British Medical Research Councils study. Am. Rev. Respir. Dis. 118:39-48.
8. East African/British Medical Research Council. 1980. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. Tubercle 61:59-69.
9. East African/British Medical Research Councils. 1973. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet i:1331-1338.
10. Falzon D, et al. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 38:516-528.
11. Hong Kong Chest Service/British Medical Research Council. 1979. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 60:201-210.
12. Hong Kong Chest Service/British Medical Research Council. 1991. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am. Rev. Respir. Dis. 143:700-706.
13. Ibrahim M, et al. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51:1011-1015.
14. Keshavjee S, et al. 2012. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int. J. Tuberc. Lung Dis. 16:596-603.
15. Kim DH, et al. 2010. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:113-119.
16. Leung ECC, Yew WW, Leung CC, Leung WM, Tam CM. 2011. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur. Respir. J. 38:227-230.
17. McCune RM, Jr, Feldmann FM, Lambert HP, McDermott W. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445-468.
18. McCune RM, Jr, McDermott W, Tompsett R. 1956. The fate of Myco-bacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763-802.
19. Migliori GB, et al. 2007. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 30:623-626.
20. Migliori GB, et al. 2008. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 31:1155-1159.
21. Migliori GB, et al. 2008. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 31:904-905.
22. Mitchison D, Davies G. 2012. The chemotherapy of tuberculosis: past, present and future. Int. J. Tuberc. Lung Dis. 16:724-732.
23. Mitchison DA. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15.
24. Mitnick C, et al. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348:119-128.
25. Monson R. 1990. Occupational epidemiology, 2nd ed. CRC Press Inc., Boca Raton, FL.
26. Nuermberger E, et al. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524.
27. Rothman KJ. 2002. Epidemiology: an introduction. Oxford University Press, Oxford, United Kingdom.
28. Schuster SC. 2008. Next-generation sequencing transforms today's biology. Nat. Methods 5:16-18.
29. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
30. Shi W, et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
31. Sokolova GB, Semenova OV, Bogadel'nikova IV, Kunichan AD. 2002. Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis. Antibiot. Khimioter. 47:12-17. (In Russian.)
32. Somner AR, Brace AA. 1966. Late results of treatment of chronic drug-resistant pulmonary tuberculosis. Br. Med. J. 1:775-778.
33. Tasneen R, et al. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492.
34. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:3664-3668.
35. Tousek J, Jancik E, Zelenka M, Jancikova-Máková M. 1967. The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up. Tubercle 48:27-31.
36. Van Deun A, et al. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:684-692.
37. van Soolingen D, et al. 2010. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 5:e12640. doi:10.1371/journal.pone.0012640.
38. Veziris N, et al. 2009. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179:75-79.
39. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. World Health Organization, Geneva, Switzerland.
40. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/ HTM/TB/2008.392. World Health Organization, Geneva, Switzerland.
41. Yew WW, et al. 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744-751.
42. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazin-amide: a review. Int. J. Tuberc. Lung Dis. 7:6-21.
43. R-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg. Microbes Infect. 1:e5.
44. Zierski M, Zachara A. 1970. Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle 51:172-177.
45. Zou G. 2004. A modified Poisson regression approach to prospective studies with binary data. Am. J. Epidemiol. 159:702-706.